Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Reverse Transcriptase Inhibitor
Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms. -
HIV Protease Inhibitor
Ro 31-8588 is a potent HIV protease inhibitor, exhibiting a Ki of 0.3 nM. This compound is essential for studying the role of HIV protease in viral replication and can be utilized in research focused on AIDS treatment and potential therapeutic strategies. Its high affinity makes it a valuable tool for investigating the mechanistic aspects of HIV inhibition. -
HIV-1 Protease Inhibitor
LY-289612 is a potent HIV-1 protease inhibitor, exhibiting an IC50 value of 1.5 nM. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby inhibiting the replication of HIV-1. It is utilized in research focused on developing antiviral therapies and understanding HIV resistance mechanisms. -
HIV-1 Protease Inhibitor
PL-100 is a powerful inhibitor of HIV-1 protease, exhibiting a Ki of 36 pM and an EC50 of 16 nM. This compound effectively inhibits viral replication by targeting HIV-1 protease activity, showing significant antiviral efficacy against drug-resistant strains of the virus. PL-100 is suitable for research applications focused on understanding and combating drug-resistant HIV infections. -
Bacterial Inhibitor
2-C-Methyl-D-erythritol 4-phosphate is an intermediate in the methylerythritol phosphate (MEP) pathway, primarily present in prokaryotes. This compound plays a crucial role as a precursor in the biosynthesis of isoprenoids and non-isoprenoids, including essential vitamins. Its unique presence in bacteria, coupled with its absence in humans, positions it as a promising target for the development of bacterium-specific therapeutic agents for infectious disease treatment. -
Bacterial Inhibitor
Ianthelliformisamine A TFA is a bacterial inhibitor that enhances antibiotic efficacy against resistant Gram-negative bacteria. It demonstrates potent bactericidal activity against Staphylococcus aureus, with an IC50 value of 3.8 μM and a minimum inhibitory concentration of 25 μM. The biological activity is attributed to the structural variations of its synthetic derivatives and their interaction with various amino ester derivatives, making it a valuable tool for research in antibiotic resistance and bacterial infections. -
Bacterial Inhibitor
Lysine hydroxamate is an amino acid hydroxamate that acts as a bacterial inhibitor by selectively reducing the growth of Escherichia coli K-12. This compound demonstrates significant antibacterial activity among amino acid hydroxamates, with a unique mechanism of action that allows for the reversible inhibition of bacterial growth through the addition of L-serine. Lysine hydroxamate provides a valuable tool for researchers investigating bacterial growth inhibition and exploring amino acid analogs in microbial studies. -
Bacterial Inhibitor
Negamycin is a bacterial inhibitor that targets protein synthesis by binding to the head domain of the bacterial ribosomal small subunit. This interaction disrupts normal translation, leading to cell death and enhancing the misreading of near-cognate codons. Negamycin is valuable for research applications focused on understanding antibiotic mechanisms and bacterial resistance. -
Bacterial Inhibitor
3-Fluoro-DL-valine is an unnatural amino acid that functions as a bacterial inhibitor by disrupting protein synthesis in targeted bacterial strains. This compound demonstrates significant antibacterial activity, making it a valuable tool in microbiological studies. Additionally, 3-Fluoro-DL-valine can be utilized in peptide synthesis, offering versatile applications for the development of bioactive peptides in biochemical research and drug discovery. Its distinct structural properties position it as a promising candidate for innovative compound research and development. -
Bacterial Inhibitor
WQ3810 is a fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, critical enzymes for DNA replication and transcription. This compound exhibits potent antibacterial activity against a range of gram-positive and gram-negative bacteria. WQ3810 is valuable for research applications focused on studying bacterial infections and developing effective antimicrobial therapies. -
Bacterial Inhibitor
Vebufloxacin is a synthetic antibacterial agent that targets bacterial DNA gyrase, leading to the inhibition of bacterial DNA replication and transcription. It demonstrates potent activity against both gram-positive and gram-negative bacteria, making it a valuable tool in studying bacterial infections and resistance mechanisms. Research applications include evaluating the efficacy of antibacterial treatments and understanding the molecular basis of bacterial survival. -
Bacterial Inhibitor
BO3482 is a bacterial inhibitor that exhibits antimicrobial activity against methicillin-resistant Staphylococci (MRS). It demonstrates a minimum inhibitory concentration (MIC90) of 6.25 mg/mL, effectively halting bacterial growth. This compound is valuable for research applications focused on antibiotic resistance and the development of new antibacterial agents. -
Bacterial Inhibitor
A7132 is a potent antibacterial agent that targets bacterial infections. This compound exhibits broad-spectrum antibacterial activity, making it a valuable tool for research applications in antimicrobial studies and the development of new therapies against bacterial resistance. A7132 is suitable for evaluating the efficacy of antibacterial compounds in various biological assays. -
β-lactamase inhibitor
ETX0282 is a β-lactamase inhibitor that functions as an orally active prodrug, converted in the liver to its active form, ETX1317. This compound demonstrates excellent stability during intestinal absorption and enhances the efficacy of antibiotics, like Cefpodoxime Proxetil, in reducing bacterial load in models of neutropenic infections. ETX0282 is useful for research focused on combating infections caused by drug-resistant Gram-negative bacteria. -
Beta-lactamase Inhibitor
Doxazosin impurity 12 is identified as a CTX-M β-lactamase inhibitor, exhibiting a Ki value of 0.7 mM against the CTX-M enzyme. This compound is valuable for research applications aimed at overcoming antibiotic resistance mediated by β-lactamases, particularly in the study of bacterial infections and the development of novel antimicrobial strategies. -
Metallo-β-Lactamase Inhibitor
Metallo-β-lactamase-IN-14 is a potent inhibitor of metallo-β-lactamases, specifically targeting VIM-1 and VIM-2 enzymes. This compound demonstrates significant antibacterial activity against Gram-negative bacteria, including Pseudomonas aeruginosa. It is a valuable tool for research applications aimed at combating resistance in clinical pathogens. -
Metallo-β-Lactamase Inhibitor
Metallo-β-lactamase-IN-13 is a potent inhibitor of metallo-β-lactamases, targeting enzymes that confer resistance in Gram-negative bacteria. This compound demonstrates significant antibacterial activity against Pseudomonas aeruginosa, making it an important tool for research into combating antibiotic resistance. Its broad-spectrum activity against various metallo-β-lactamases supports investigations into novel therapeutic strategies for treating resistant bacterial infections. -
β-lactamase II Inhibitor
N-Cbz-D-Cysteine is a potent inhibitor of β-lactamase II with a Ki value of 20.1 µM. This compound can be utilized in the study of antibiotic resistance mechanisms and the development of novel β-lactamase inhibitors. N-Cbz-D-Cysteine's biological activity makes it a valuable reagent in research focusing on antimicrobial strategies and enzymatic inhibition. -
β-lactamase II Inhibitor
N-Cbz-L-Cysteine is a potent inhibitor of β-lactamase II, demonstrating a Ki value of 97 µM. This compound is useful in biochemical research aimed at overcoming antibiotic resistance by targeting β-lactamase enzymes. N-Cbz-L-Cysteine may be employed in studies exploring the inhibition of β-lactamase-mediated antibiotic degradation and enhancing the efficacy of β-lactam antibiotics. -
Beta-lactamase Inhibitor
Xeruborbactam isoboxil is a novel beta-lactamase inhibitor that effectively targets and inhibits the activity of various beta-lactamases. Its primary mechanism involves the binding to the active site of these enzymes, preserving the efficacy of beta-lactam antibiotics. This compound is particularly valuable in combating antibiotic resistance and is utilized in research focused on understanding and overcoming beta-lactam resistance in bacterial infections. -
β-lactamase Inhibitor
GT-055 is a potent β-lactamase inhibitor that demonstrates broad-spectrum activity against a variety of β-lactamase enzymes. This compound effectively enhances the efficacy of β-lactam antibiotics by preventing their hydrolysis, making it a valuable tool in combating antibiotic resistance. GT-055 is suitable for research applications focused on understanding β-lactamase mechanisms and developing new therapeutic strategies. -
Metallo-β-lactamases (MBLs) Inhibitor
epi-D-Captopril is a stereoisomer of Captopril that serves as an inhibitor of metallo-β-lactamases (MBLs). It demonstrates inhibitory activity with IC50 values against NDM-1, IMP-1, and VIM-2 of 64 μM, 173 μM, and 5.5 μM, respectively. This reagent is useful for research applications focused on understanding and addressing drug-resistant bacterial infections associated with MBLs. -
Beta-lactamase Inhibitor
ANT431 is a metallo-β-lactamase inhibitor that enhances the efficacy of beta-lactam antibiotics, particularly Meropenem. This compound is designed for applications in combating antibiotic resistance by restoring the effectiveness of β-lactam antibiotics in bacterial infections, specifically in models involving Escherichia coli. Its potential utility in therapeutic contexts makes it a valuable reagent for microbiological and pharmacological research. -
β-lactamase Inhibitor
Izumenolide is a potent β-lactamase inhibitor derived from the strain Micromonospora chalcea subsp. izumensis. It exhibits significant inhibitory activity against certain β-lactamases, with an IC50 value of 0.01 μg/mL specifically for TEM-2 β-lactamase. This compound is valuable for research applications focused on antibiotic resistance and the development of new therapeutic strategies targeting bacterial infections. -
Influenza Viru Inhibitor
(E/Z)-RA-0002034 is an inhibitor targeting the protease activity of the Chikungunya virus (CHIKV) nsP2, with an IC50 value of 58 nM. This compound covalently modifies the catalytic cysteine residue in a site-specific manner, leading to the inhibition of viral replication. It serves as a valuable tool for studying CHIKV biology and developing antiviral therapies against Chikungunya virus infections. -
HIV Replication Inhibitor
PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication, demonstrating significant antiviral activity. In addition to its efficacy against HIV, PMEDAP exhibits anti-murine cytomegalovirus (MCMV) properties and effectively inhibits Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. This compound is valuable for research applications focused on viral pathogenesis and therapeutic interventions in retroviral infections. -
HSV/MCMV Inhibitor
Rociclovir is an acyclic nucleoside derivative that functions as an inhibitor of herpes simplex virus (HSV) and murine cytomegalovirus (MCMV). It has demonstrated protective effects in murine models against HSV and MCMV infections. However, it is important to note that Rociclovir exhibits limited antiviral activity in cell culture systems, highlighting its primary utility in in vivo research applications. -
Dengue Virus Inhibitor
Mosnodenvir is an orally active pan-serotype inhibitor of the dengue virus (DENV), exhibiting EC50 values between 0.057 and 11 nM across four DENV serotypes. Its primary mechanism involves inhibiting the interaction between nonstructural proteins NS3 and NS4B, which is critical for preventing the replication of viral RNA. With demonstrated picomolar to nanomolar antiviral activity in vitro, Mosnodenvir also shows antiviral efficacy in murine and non-human primate models, making it a valuable tool for research into dengue virus treatment. -
NS4B Inhibitor
NITD-688 is an orally active inhibitor targeting the NS4B protein of the dengue virus. This compound exhibits pan-serotype activity against various strains of dengue virus (DENV) and is essential for investigating the molecular mechanisms of dengue virus replication. NITD-688 serves as a valuable tool in the development of antiviral strategies and therapeutic interventions for dengue virus infections. -
Translation Elongation Inhibitor
Lactimidomycin is a glutarimide-containing compound that functions as a potent inhibitor of eukaryotic translation elongation. It demonstrates significant antiproliferative effects on various tumor cell lines and selectively disrupts protein synthesis, with an IC50 value of 37.82 nM. Additionally, Lactimidomycin exhibits strong antiviral activity against dengue virus 2 and other RNA viruses, making it a valuable reagent for cancer research and antiviral studies. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-2 is a potent inhibitor of the dengue virus (DENV) NS2B/NS3 protease, demonstrating an IC50 of 6.0 nM and a Ki of 0.66 µM. This covalent inhibitor exhibits no cytotoxicity and significantly enhances cell survival rates, making it an important tool for research in dengue virus therapeutics and antiviral development. -
Dengue Viral Inhibitor
1,8-Dihydroxy-4,5-dinitroanthraquinone is an effective inhibitor of the dengue viral serine proteinase NS2B/3. This compound demonstrates significant antiviral activity with an IC50 of 4.2 μM against viral replication, while also exhibiting proteinase inhibition with an IC50 of 432 μM. Additionally, 1,8-Dihydroxy-4,5-dinitroanthraquinone disrupts NS2B/3 cleavage in BHK-21 cells, providing a valuable tool for research into dengue virus mechanisms and potential therapeutic strategies. -
RdRp Inhibitor
HeE1-2Tyr is a pyridobenzothiazole compound that serves as an inhibitor of RNA-dependent RNA polymerases (RdRp) in flavivirus. It demonstrates significant inhibitory activity against West Nile, Dengue, and SARS-CoV-2 RdRps, with an IC50 value of 27.6 μM in vitro. HeE1-2Tyr is valuable for research investigating viral replication and potential therapeutic strategies targeting RNA polymerase activity. -
RNA Viral Inhibitor
KIN101 is a potent RNA viral inhibitor, demonstrating IC50 values of 2 µM and >5 µM against influenza virus and Dengue virus (DNV), respectively. It acts as an isoflavone agonist of IRF-3 dependent signaling, promoting the nuclear translocation of IRF-3. This compound exhibits broad-spectrum antiviral activity against various RNA viruses, making it a valuable tool for research in virology and antiviral therapeutics. -
Dengue Viru Inhibitor
SP187 is a host-targeted iminosugar that inhibits Dengue virus replication by interfering with viral glycan processing. This compound has demonstrated antiviral activity against both filovirus and influenza infections in vitro and in vivo. SP187 serves as a valuable research tool for studying dengue virus biology and developing therapeutic strategies for viral infections. -
HCV NS3 Helicase Inhibitor
ML283 is a potent inhibitor of the HCV NS3 helicase, with an IC50 value of 2.6 μM. Additionally, ML283 displays inhibitory activity against the dengue virus (DenV) ATPase, with an IC50 of 4.0 μM. This compound is valuable for research focused on hepatitis C virus and dengue virus replication mechanisms, providing a tool for the development of antiviral therapies. -
Influenza Virus Inhibitor
Glabranine is a flavonoid compound recognized for its inhibitory effects against the influenza virus. Isolated from Tephrosia species, it demonstrates significant interaction with the soluble ectodomain of the dengue virus type 2 (DENV2) E protein, suggesting potential applications in antiviral research. This compound serves as a valuable tool for investigating the mechanisms of viral inhibition and offers insights into therapeutic strategies against influenza and related viral infections. -
Dengue Virus Protease Inhibitor
SP-471 is a potent inhibitor of the dengue virus (DENV) protease, demonstrating an IC50 value of 18 μM. It effectively targets both intermolecular and intramolecular protease activities, making it a valuable tool for research on dengue virus pathogenesis and antiviral drug development. This compound is suitable for studies focused on elucidating viral protease mechanisms and testing potential therapeutic interventions. -
AChE Inhibitor
Temephos is an organophosphate insecticide that functions as an irreversible inhibitor of acetylcholinesterase (AChE). This inhibition leads to cholinergic overactivation, effectively disrupting the larval development of Aedes aegypti and Aedes albopictus, making it a valuable tool in research concerning Dengue Virus, Zika Virus, and other mosquito-borne pathogens. While exhibiting important biological activity, Temephos has been shown to cause genotoxicity, neurodevelopmental toxicity, and potential liver and reproductive system effects in mammals. Additionally, it can accumulate in adipose tissues and aquatic organisms, with its metabolism primarily occurring through oxidation and hydrolysis. Temephos serves as a critical reagent in studies of vector control and viral transmission dynamics. -
Dengue Viru Inhibitor
BP13944 is a small molecule inhibitor that targets the dengue virus (DENV) by inhibiting its NS3 protease. It demonstrates significant antiviral activity, effectively suppressing the replication of all four DENV serotypes with an EC50 value of 1.03±0.09 μM, while showing no toxicity to host cells. Notably, the presence of the E66G mutation in the NS3 protease confers resistance to BP13944. As a promising candidate for dengue virus intervention, BP13944 represents a potential therapeutic agent in the absence of effective vaccines or treatments for dengue. -
Dengue Viru Inhibitor
ST-148 is a novel small molecule compound that acts as a potent inhibitor of all four serotypes of the dengue virus. In studies using a nonlethal AG129 mouse model, ST-148 significantly decreased viremia and viral load in key organs, while also showing a tendency to reduce plasma cytokine levels. The mechanism of action involves direct interaction with the dengue virus capsid protein, indicating that ST-148 interferes with specific stages of the viral replication cycle, which may provide avenues for therapeutic development against dengue virus infections. -
DENV-1/DENV-2 Inhibitor
DENV-IN-12 is a potent inhibitor targeting Dengue Virus serotypes 1 and 2. This compound, a derivative of N-methylcytisine thio, demonstrates significant antiviral activity against DENV-2, with EC50 values ranging from 0.002 to 0.005 μM across various cell lines. DENV-IN-12 serves as a valuable tool for research applications focused on understanding dengue virus pathogenesis and developing antiviral therapeutics. -
DENV2 Inhibitor
DENV-IN-9 (Compound 5f) is a potent inhibitor of the dengue virus serotype 2 (DENV2), exhibiting an EC50 of 0.88 μM. This compound effectively curtails viral replication, making it a valuable tool for research focused on dengue virus pathology and potential antiviral therapeutic strategies. Its potency and specificity position DENV-IN-9 as a significant candidate for studies aimed at understanding DENV2 inhibition mechanisms. -
DENV2 Inhibitor
DENV-IN-8 is a selective DENV2 inhibitor that exhibits an EC50 value of 0.068 μM. This compound effectively disrupts viral replication, making it a valuable tool for research aimed at understanding dengue virus pathogenesis and developing antiviral strategies. Its high potency and specificity for DENV2 facilitate studies in virology and drug discovery. -
RdRp Domain Inhibitor
NITD-203 is an inhibitor targeting the RNA-dependent RNA polymerase (RdRp) domain. It exhibits potent inhibitory activity against all four serotypes of dengue virus (DENV), as well as yellow fever virus (YFV) and West Nile virus (WNV). This compound is valuable for research applications focusing on the development of antiviral therapies and understanding the molecular mechanisms of viral replication. -
DENV Inhibitor
DENV-IN-10 is a potent tetravalent inhibitor targeting dengue virus (DENV). It demonstrates effective suppression of DENV replication with EC50 values of 1.36, 0.87, 0.94, and 0.95 μM against DENV serotypes 1-4, respectively. This compound functions as a post-entry replication inhibitor, exhibiting specificity for primate-derived cells, making it a valuable tool for research into dengue virus biology and therapeutic intervention. -
DENV Inhibitor
SDM25N is a Dengue virus (DENV) inhibitor that targets the NS4B protein, effectively disrupting genomic RNA replication. With an EC50 of 1.9 µM, SDM25N demonstrates cell type-specific inhibition of DENV. This compound is valuable for research into DENV infection and the mechanisms of viral replication. -
Endoplasmic Reticulum α-glucosidase II (GluII) Inhibitor
ToP-DNJ is a specific inhibitor of endoplasmic reticulum α-glucosidase II (GluII), demonstrating an IC50 value of 9.0 μM. It selectively interferes with both catalytic reactions of GluII, showing enhanced activity in the initial conversion of di-glycosylated to mono-glycosylated glycans. Additionally, ToP-DNJ exhibits anti-DENV activity, making it a valuable tool for research into dengue virus infection and related glycobiology studies. -
NS4B Inhibitor
JMX0254 is a potent inhibitor of the dengue virus NS4B protein, exhibiting oral bioavailability. It displays effective antiviral activity with EC50 values of 0.78 µM, 0.16 µM, and 0.035 µM against DENV-1, DENV-2, and DENV-3, respectively. This compound is valuable for research applications focused on understanding and combating dengue virus infections. -
Influenza Viru Inhibitor
SP187 hydrochloride is a host-targeting iminosaccharide that primarily inhibits endoplasmic reticulum glucosidase, rendering it effective against filovirus infections. This compound demonstrates antiviral activity, notably against the Dengue virus, in vivo. SP187 hydrochloride is a valuable tool for researchers investigating antiviral mechanisms and developing therapeutic strategies against viral infections.
